Carmelo Gurnari: Overexcited for this achievement shedding new insights into PNH clinico-biological features

Carmelo Gurnari, Hematologist/Oncologist and Researcher at Cleveland Clinic, posted on X:

“Overexcited for this achievement shedding new insights into PNH clinico-biological features ‘Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043 patient/years analysis’ out in Blood Journal.’

– Among 267 patients followed up for a total of 2043 patients/years, 56 (21%) developed TE.
– Thrombosis in atypical sites (eg, Budd-Chiari) is often the first sign of PNH, and anti-coagulation/anti-complement combination is the mainstay of treatment.
– DOACs are potential options for PNH-related TE and discontinuation is safe in cases with complete control of hemolysis. DOACs
– No TE recurrence was observed in 19 patients treated with.
– 14 cases discontinued anti-coagulation without TE recurrence at a median time of 51 months.

Read further.
Source: Carmelo Gurnari/X